查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1401849

2030 年藥物研發發現市場預測的藥物化學：按工藝、設計、藥物類型、治療領域、最終用戶和地區進行的全球分析

Medicinal Chemistry For Drug Discovery Market Forecasts to 2030 - Global Analysis By Process, Design, Drug Type, Therapeutic Area, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，到 2023 年，藥物研發市場將達到 925 億美元，預計在預測期內將以 13.5% 的複合年成長率成長，到 2030 年將達到 2,244.5 億美元。

用於藥物藥物研發的藥物化學是一個跨學科領域，結合了化學、生物學和藥理學原理來設計和開發新的藥物化合物。其目的是識別和最佳化具有治療潛力的分子，同時考慮安全性、有效性和作用機制等因素，最終創造出治療疾病的新藥。

根據世界衛生組織 (WHO) 統計，每年有近 1800 萬人死於心血管疾病，使其成為全球第一大死因。

擴大醫療設施

醫療保健基礎設施的擴展和可近性增加了對新製藥解決方案的需求。此次擴建包括建立新的醫院、診所和研究中心，為臨床和藥物試驗提供平台。此外，改善的醫療設施將加強患者護理，並改善各種醫療狀況的診斷和治療。此外，設施擴建將透過吸引公共和私營部門的投資、支持研究以及促進製藥公司和醫療機構之間的合作，加速新藥的發現和發展。

開發成本上升

新藥從發現到核准的過程需要資本密集的過程，包括臨床前測試、廣泛的臨床試驗和監管集中。這些成本包括研究、人員、基礎設施以及遵守嚴格的安全性和有效性標準。這些成本的經濟負擔可能會阻礙對潛在致命的候選藥物的投資，限制獲得先進治療方法的機會，並最終阻礙該領域的進展，延遲為患者提供新的治療方法。

整合數位健康和​​人工智慧

人工智慧和數位健康技術使藥物研究人員能夠處理大量資料集，加速潛在候選藥物的識別並預測其在生物系統中的行為。機器學習演算法可以透過分析分子結構和識別藥物-標靶相互作用來簡化先導化合物最佳化過程。這些技術還將支持遠端患者監護和真實世界證據生成，以改善藥物安全性和療效評估。人工智慧與數位健康之間的協同效應不僅將加速藥物研發，還將帶來更個體化和有效的治療，為製藥業帶來重大投資和創新。因此，這些技術正在推動市場成長。

故障率高

由於安全問題、無效和意想不到的副作用，大多數潛在的藥物組合從未進入市場。藥物開發過程受到不確定性的困擾。此外，此類失敗可能會為製藥公司帶來重大財務損失，並阻礙研究投資。在不成功的藥物上花費大量時間和資源會阻礙技術創新並限制新治療方法的獲得，最終解決未滿足的醫療需求並改善患者的治療結果。這將削弱製藥業的能力。

COVID-19 的影響

COVID-19大流行對藥物研發的藥物化學市場產生了重大影響。在加速 COVID-19 治療和疫苗研究的同時，它擾亂了非 COVID-19 藥物的開發，導致資源的延遲和重新分配。封鎖影響了實驗室工作和臨床試驗。協作和資料共用有所增加，以促進研究。監管機構也進行了調整併加快了核准。長期影響包括研究重點的轉變，重點放在疫苗開發和抗病毒療法上，以及重新關注全球衛生安全。

生技藥品產業預計將在預測期內成為最大的產業

生技藥品產業估計佔最大佔有率。生技藥品是從生物資源中提取的一類藥物。單株抗體、蛋白質和核酸等複雜分子是治療藥物開發的重點。生物製藥旨在高精確度針對特定疾病途徑，為多種疾病提供有效的治療方法，包括自體免疫疾病、癌症和罕見疾病。此外，生技藥品的開發涉及複雜的藥物化學、基因工程和生物技術。生物製藥正在徹底改變醫療保健，提供創新且經常改變生活的治療選擇，並且是製藥業快速成長和發展的一部分。

腫瘤學領域預計在預測期內複合年成長率最高

預計腫瘤學領域在預測期內將出現良好的成長。腫瘤學是醫學和醫學科學的一個分支，專注於發現和開發用於診斷、預防和治療各種癌症的專用藥物。癌症的盛行率和複雜性使其成為一個重要的研究領域。腫瘤學領域的藥物化學家設計和最佳化針對癌細胞、破壞疾病途徑並增強人體抗癌能力的分子。此外，這些治療方法包括傳統化療、標靶治療、免疫療法和新方法，推動不斷創新，以應對世界上最具挑戰性的健康問題。

佔有率最大的地區

在估計期間，亞太地區佔據最大的市場佔有率。亞太地區在藥物研發的藥物化學市場中扮演重要角色。亞太地區包括許多醫療基礎設施和研究能力不斷增強的國家。中國、印度、日本和韓國是藥物研究和製造的主要中心。該地區受益於較低的研究成本，並吸引了全球製藥公司的投資。此外，亞太地區是全球藥物化學藥物研發市場中充滿活力且重要的部分，為接觸廣大患者群體進行合作研究、臨床試驗和新藥試驗提供了機會。

複合年成長率最高的地區：

預計北美在預測期內將實現盈利成長。美國和加拿大是許多大型製藥企業、知名研究機構和強大的醫療基礎設施的所在地，是專注於基因組學和生技藥品等最尖端科技的創新中心。此外，該地區受益於強力的智慧財產權保護，促進了藥物開發和商業化。北美繼續處於藥物研發的前沿，經常設定藥物研究和開發的全球趨勢和標準。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章藥物研發的全球藥物化學市場：依流程

  • 目標選擇
  • 候選人檢驗
  • 點選讀取識別
  • 潛在客戶最佳化

第6章藥物研發的全球藥物化學市場：設計

  • 基於片段的變化
  • 面向多樣性的綜合
  • 基於結構的藥物設計
  • 天然產物
  • 化學基因體學
  • 其他設計

第7章按藥物類型藥物研發的全球藥物化學市場

  • 生技藥品
  • 低分子

第8章藥物研發的全球藥物化學市場：按治療領域

  • 腫瘤學
  • 感染疾病和免疫系統疾病
  • 神經病學
  • 消化器官系統疾病
  • 心血管疾病
  • 其他治療領域

第9章藥物研發的全球藥物化學市場：按最終用戶分類

  • 合約研究組織
  • 學術研究所
  • 製藥和生物技術公司
  • 其他最終用戶

第10章全球藥物研發化學市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第11章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司簡介

  • Eurofins Scientific
  • WuXi Apptec
  • Labcorp Drug Development
  • Charles River
  • Evotec SE
  • Charles River
  • Piramal Pharma Solutions
  • Certara USA
  • Pfizer, Inc.
  • Sygnature Discovery Limited
  • Jubilant Biosys Ltd.
  • Malvern Panalytical Ltd
  • Taros Chemicals GmbH & Co. KG
  • Nereid Therapeutics Inc.
  • Genscript Biotech Corporation
  • BioBlocks, Inc.
  • Domainex
  • Aurelia Biosciences Ltd.
  • Thermo Fisher Scientific Inc.
  • Spectris Plc
Product Code: SMRC24369

According to Stratistics MRC, the Global Medicinal Chemistry For Drug Discovery Market is accounted for $92.50 billion in 2023 and is expected to reach $224.45 billion by 2030 growing at a CAGR of 13.5% during the forecast period. Medicinal chemistry for drug discovery is a multidisciplinary field that combines principles of chemistry, biology, and pharmacology to design and develop new pharmaceutical compounds. It aims to identify and optimise molecules with therapeutic potential, considering factors such as safety, efficacy, and mechanism of action, ultimately leading to the creation of novel drugs for the treatment of diseases.

According to the World Health Organization, the cardiovascular diseases results in almost 18 million deaths each year and it is the leading cause of death across the globe.

Market Dynamics:

Driver:

Expanding healthcare facilities

The expanding and improved accessibility of healthcare infrastructure raises the need for novel pharmaceutical solutions. This expansion includes the establishment of new hospitals, clinics, and research centres, providing a platform for clinical trials and drug testing. Additionally, improved healthcare facilities enhance patient care, leading to greater diagnosis and treatment of various medical conditions. Moreover, expanding facilities attracts investments from both the public and private sectors, supports research, and fosters collaboration between pharmaceutical companies and healthcare institutions, which accelerates the discovery and development of new drugs.

Restraint:

Rising development costs

The process of bringing a new drug from discovery to market approval is capital-intensive, encompassing preclinical studies, extensive clinical trials, and regulatory compliance. These expenses include research, personnel, infrastructure, and compliance with rigorous safety and efficacy standards. The financial burden of these expenses may deter investment in potentially lethal drug candidates and restrict access to advanced therapies, ultimately hindering the field's advancement as well as delaying the release of novel treatments for patients.

Opportunity:

Integration of digital health and AI

AI and digital health technologies enable pharmaceutical researchers to process vast datasets, accelerating the identification of potential drug candidates and predicting their behaviour in biological systems. Machine learning algorithms can analyse molecular structures and identify drug-target interactions, streamlining the lead optimisation process. These technologies also support remote patient monitoring and real-world evidence generation, improving drug safety and efficacy assessments. The synergy between AI and digital health not only expedites drug discovery but also holds the promise of more personalised and effective therapies, attracting substantial investment and innovation in the pharmaceutical industry. Thus, these technologies are propelling market growth.

Threat:

High failure rates

The majority of potential medication combinations do not reach the market because of safety issues, ineffectiveness, or unexpected adverse effects. The drug development process is plagued with uncertainty. Moreover, these failures result in substantial financial losses for pharmaceutical companies and can deter investment in research. The extensive time and resources invested in unsuccessful drugs can hinder innovation and limit the availability of novel therapies, ultimately compromising the industry's ability to address unmet medical needs and improve patient outcomes.

COVID-19 Impact

The COVID-19 pandemic has had a significant impact on the medicinal chemistry market for drug discovery. While it accelerated research for COVID-19 treatments and vaccines, it disrupted non-COVID drug development, causing delays and reallocating resources. Lockdowns affected laboratory work and clinical trials. Collaboration and data sharing have increased to expedite research. Regulatory agencies adapted, expediting approvals. The long-term impact includes changes in research priorities, emphasising vaccine development and antiviral therapies, as well as a renewed emphasis on global health security.

The Biologics segment is expected to be the largest during the forecast period

The Biologics segment is estimated to hold the largest share. Biologics are a class of medicinal products derived from biological sources. These complex molecules, such as monoclonal antibodies, proteins, and nucleic acids, are focused on the development of therapeutic drugs. Biologics are designed to target specific disease pathways with high precision, offering effective treatments for various conditions, including autoimmune disorders, cancer, and rare diseases. Moreover, the development of biologics involves intricate medicinal chemistry, genetic engineering, and biotechnology techniques. Biologics have revolutionised healthcare, providing innovative and often life-changing treatment options, and represent a rapidly growing and evolving sector within the pharmaceutical industry.

The Oncology segment is expected to have the highest CAGR during the forecast period

The Oncology segment is anticipated to have lucrative growth during the forecast period. Oncology is the branch of medicine and medical science that focuses on the discovery and development of drugs specifically for the diagnosis, prevention, and treatment of various forms of cancer. It is a critical area of research due to the prevalence and complexity of cancer. Medicinal chemists in the oncology field design and optimise molecules that target cancer cells, disrupt disease pathways, or enhance the body's ability to fight cancer. In addition, these therapies can include traditional chemotherapies, targeted therapies, immunotherapies, and novel approaches, driving continuous innovation to combat one of the world's most challenging health issues

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period. The Asia-Pacific region plays a vital role in the medicinal chemistry market for drug discovery. It encompasses diverse countries with growing healthcare infrastructure and research capabilities. China, India, Japan, and South Korea are key hubs for pharmaceutical research and production. The region benefits from lower research costs, attracting investment from global pharmaceutical companies. Furthermore, Asia-Pacific offers opportunities for collaborative research, clinical trials, and access to a vast patient population for testing new drugs, making it a dynamic and significant segment of the global medicinal chemistry for drug discovery market.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period. In the United States and Canada, which host many leading pharmaceutical and biotechnology companies, renowned research institutions, and robust healthcare infrastructure, North America is a hub for innovation, with a focus on cutting-edge technologies like genomics and biologics. Moreover, the region benefits from strong intellectual property protection, facilitating drug development and commercialization. North America remains at the forefront of drug discovery, often setting global trends and standards in pharmaceutical research and development.

Key players in the market:

Some of the key players in the Medicinal Chemistry For Drug Discovery Market include Eurofins Scientific, WuXi Apptec, Labcorp Drug Development, Charles River, Evotec SE, Charles River, Piramal Pharma Solutions, Certara USA, Pfizer, Inc., Sygnature Discovery Limited, Jubilant Biosys Ltd., Malvern Panalytical Ltd, Taros Chemicals GmbH & Co. KG, Nereid Therapeutics Inc., Genscript Biotech Corporation, BioBlocks, Inc., Domainex, Aurelia Biosciences Ltd., Thermo Fisher Scientific Inc. and Spectris Plc.

Key Developments:

In October 2023, Pfizer Inc. and BioNTech SE announced positive topline results from a Phase 1/2 study evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age. The data from the trial showed that the companies' lead formulations demonstrated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains.

In October 2023, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved PENBRAYA (meningococcal groups A, B, C, W and Y vaccine), the first and only pentavalent vaccine that provides coverage against the most common serogroups causing meningococcal disease in adolescents and young adults 10 through 25 years of age.

In October 2023, Labcorp, a global leader of innovative and comprehensive laboratory services, announced the launch and national availability of its ATN Profile, a blood-based test that combines three, well-researched blood biomarkers to identify and assess biological changes associated with Alzheimer's disease - amyloid plaques, tau tangles and neurodegeneration (ATN) - which can help accelerate the path to diagnosis and intervention.

In October 2023, Labcorp, a global leader of innovative and comprehensive laboratory services, announced that it acquired Baystate Health, Inc.'s outreach laboratory business and select operating assets, including laboratory service centers operated by Baystate Health throughout Massachusetts..

Processes Covered:

  • Target Selection
  • Candidate Validation
  • Hit-to-Lead Identification
  • Lead Optimization

Designs Covered:

  • Fragment-Based Variation
  • Diversity Oriented Synthesis
  • Structure Based Drug Design
  • Natural Products
  • Chemogenomics
  • Other Designs

Drug Types Covered:

  • Biologics
  • Small Molecules

Therapeutic Areas Covered:

  • Oncology
  • Infectious and Immune System Diseases
  • Neurology
  • Digestive System Diseases
  • Cardiovascular Diseases
  • Other Therapeutic Areas

Regions Covered:

  • Contract Research Organization
  • Academic and Research Institutes
  • Pharmaceutical and Biotechnology Companies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Medicinal Chemistry For Drug Discovery Market, By Process

  • 5.1 Introduction
  • 5.2 Target Selection
  • 5.3 Candidate Validation
  • 5.4 Hit-to-Lead Identification
  • 5.5 Lead Optimization

6 Global Medicinal Chemistry For Drug Discovery Market, By Design

  • 6.1 Introduction
  • 6.2 Fragment-Based Variation
  • 6.3 Diversity Oriented Synthesis
  • 6.4 Structure Based Drug Design
  • 6.5 Natural Products
  • 6.6 Chemogenomics
  • 6.7 Other Designs

7 Global Medicinal Chemistry For Drug Discovery Market, By Drug Type

  • 7.1 Introduction
  • 7.2 Biologics
  • 7.3 Small Molecules

8 Global Medicinal Chemistry For Drug Discovery Market, By Therapeutic Area

  • 8.1 Introduction
  • 8.2 Oncology
  • 8.3 Infectious and Immune System Diseases
  • 8.4 Neurology
  • 8.5 Digestive System Diseases
  • 8.6 Cardiovascular Diseases
  • 8.7 Other Therapeutic Areas

9 Global Medicinal Chemistry For Drug Discovery Market, By End User

  • 9.1 Introduction
  • 9.2 Contract Research Organization
  • 9.3 Academic and Research Institutes
  • 9.4 Pharmaceutical and Biotechnology Companies
  • 9.5 Other End Users

10 Global Medicinal Chemistry For Drug Discovery Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Eurofins Scientific
  • 12.2 WuXi Apptec
  • 12.3 Labcorp Drug Development
  • 12.4 Charles River
  • 12.5 Evotec SE
  • 12.6 Charles River
  • 12.7 Piramal Pharma Solutions
  • 12.8 Certara USA
  • 12.9 Pfizer, Inc.
  • 12.10 Sygnature Discovery Limited
  • 12.11 Jubilant Biosys Ltd.
  • 12.12 Malvern Panalytical Ltd
  • 12.13 Taros Chemicals GmbH & Co. KG
  • 12.14 Nereid Therapeutics Inc.
  • 12.15 Genscript Biotech Corporation
  • 12.16 BioBlocks, Inc.
  • 12.17 Domainex
  • 12.18 Aurelia Biosciences Ltd.
  • 12.19 Thermo Fisher Scientific Inc.
  • 12.20 Spectris Plc

List of Tables

  • Table 1 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Process (2021-2030) ($MN)
  • Table 3 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Target Selection (2021-2030) ($MN)
  • Table 4 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Candidate Validation (2021-2030) ($MN)
  • Table 5 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Hit-to-Lead Identification (2021-2030) ($MN)
  • Table 6 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Lead Optimization (2021-2030) ($MN)
  • Table 7 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Design (2021-2030) ($MN)
  • Table 8 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Fragment-Based Variation (2021-2030) ($MN)
  • Table 9 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Diversity Oriented Synthesis (2021-2030) ($MN)
  • Table 10 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Structure Based Drug Design (2021-2030) ($MN)
  • Table 11 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Natural Products (2021-2030) ($MN)
  • Table 12 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Chemogenomics (2021-2030) ($MN)
  • Table 13 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Other Designs (2021-2030) ($MN)
  • Table 14 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 15 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Biologics (2021-2030) ($MN)
  • Table 16 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Small Molecules (2021-2030) ($MN)
  • Table 17 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Therapeutic Area (2021-2030) ($MN)
  • Table 18 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 19 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Infectious and Immune System Diseases (2021-2030) ($MN)
  • Table 20 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 21 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Digestive System Diseases (2021-2030) ($MN)
  • Table 22 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Cardiovascular Diseases (2021-2030) ($MN)
  • Table 23 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)
  • Table 24 Global Medicinal Chemistry For Drug Discovery Market Outlook, By End User (2021-2030) ($MN)
  • Table 25 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Contract Research Organization (2021-2030) ($MN)
  • Table 26 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
  • Table 27 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 28 Global Medicinal Chemistry For Drug Discovery Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.